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years, was 95.1% in the case of GCSF+plerixafor therapy compared to 42.61% for 
GCSF. Additionally, the average reported cost for GCSF+plerixafor treatment in suc-
cessful cases was $35,020, and in the case of a GCSF treatment the cost totaled 
US$93,325, which represents a 62% saving for an actual year of therapy. Therefore, 
the GCSF+Plerixafor treatment results in a more effective, less costly, and ﬁnally the 
most viable alternative. CONCLUSIONS: The GCSF+Plerixafor treatment is a cost 
effective alternative, from a Mexican institutional perspective for Non Hodgkin’s 
Lymphoma patients in preparation for an autologous hematopoietic stem cell 
transplantation.
PCN71
COST EFFECTIVENESS ANALYSIS OF BREAST CANCER RISK 
REDUCTION THERAPY: COMPARING TAMOXIFEN AND RALOXIFENE
Poon JL, Hay J
University of Southern California, Los Angeles, CA, USA
OBJECTIVES: To illustrate the relative value of raloxifene compared to tamoxifen, 
in the chemoprevention of invasive breast cancer in postmenopausal women in the 
United States. METHODS: Using outcomes data from the NSABP P-2 trial, a back-
ward induction model was performed from the societal perspective, comparing tamox-
ifen and raloxifene in postmenopausal women aged 35 to 80 years, with base case 
5-year breast cancer risk of 4.03%. Secondary outcomes considered were thrombo-
embolic events, cataracts, uterine hyperplasia and hysterectomy. Quality adjusted life 
years (QALY) gained from using raloxifene versus tamoxifen was estimated by con-
sidering the quality adjusted life expectancies for all model outcomes for each drug. 
Costs were in 2009 US dollars and costs and outcomes were discounted at an annual 
rate of 3%. An incremental cost effectiveness ratio (ICER) decision threshold of 
US$150000/QALY gained was used to determine age-cohort speciﬁc cost-effective-
ness. One-way sensitivity analyses were performed on outcome parameters and the 
discount rate, and threshold analyses were performed on parameters the model was 
sensitive to. RESULTS: Raloxifene was found to be cost effective relative to tamoxifen 
for all age-cohorts in the model, with ICERs between US$25,631 and US$30,133/
QALY gained at age 60 and 35 respectively. The model was most sensitive to raloxi-
fene cost, the ICER varying by +/-26.5% when the cost varied by +/-25%. The model 
was also sensitive to the probability of developing cataracts and requiring a hysterec-
tomy when on tamoxifen therapy. For raloxifene to not be cost-effective raloxifene 
costs would have to increase 5.7 times or the probability of developing cataracts or 
requiring hysterectomy when on tamoxifen therapy would have to reduce to zero and 
by 21 times respectively. CONCLUSIONS: Raloxifene was found to be cost effective 
compared to tamoxifen in the target population due to its more favourable adverse 
effect proﬁle, despite both drugs having similar efﬁcacy in the chemoprevention of 
breast cancer.
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OBJECTIVES: Elaborate an economic evaluation based in a cost-effectiveness model 
to compare sunitinib versus interferon-α (IFNα) and bevacizumab + IFNα as ﬁrst line 
therapy for metastatic renal clear cell carcinoma, in Brazilian Private Health System 
perspective. METHODS: A Markov model, with 6 weeks cycles and a 2-year time 
horizon was developed in Microsoft Excel to evaluate the cost-effectiveness of suni-
tinib vs. IFNα and bevacizumab + IFNα, considering resources from the Brazilian 
Private Health Care. The model considered that the patients received active treatment 
until drug fail. After progression conﬁrmation, patients were treated with a second 
line of active treatment or best supportive care (progression monitoring and palliative 
treatment). Results were expressed as life-years (LY) gained, progression-free LY 
(PFLY) gained, treatment costs, and incremental cost-effectiveness ratios (ICER) 
RESULTS: In comparison with IFNα, sunitinib increases LY and PFLY by 0.08 and 
0.33 years respectively, with ICER of R$324,172 (US$190,689 Purchasing Power 
Parity 2009, 1US$ = 1,7R$). In comparison with bevacizumab + IFNα, sunitinib was 
dominant as both more effective (with 0.04 LY and 0.09 PFLY gained) and less costly, 
with a negative ICER of R$ 2,169,212 (US$ 1,549,437) over 2 years, meaning a cost 
saving of R$ 2,169,212 over the combination therapy. CONCLUSIONS: This model 
suggests that when taking the perspective of the Brazilian Private Health Care System 
, sunitinib achieved overall cost saving with improved survival when compared with 
bevacizumab + IFNα in a 2 years time horizon. In comparison to IFNα, sunitinib 
promoted better results on efﬁcacy parameters, with an incremental cost in the same 
time horizon.
PCN73
COST-EFFECTIVENESS ANALYSIS OF MULTIMODAL SCREENING FOR 
OVARIAN CANCER
Ding Y, Hay J
University of Southern California, Los Angeles, CA, USA
OBJECTIVES: The main objective was to assess cost-effectiveness of multimodal 
screening for ovarian cancer (Annual screening with CA125 marker, followed by 
transvaginal ultrasound for those at increased risk according to CA125 level) from the 
US societal perspective. The secondary objective was to facilitate an economic compari-
son between two different screening strategies (multimodal screening and ultrasound 
screening), which have been proven to be effective in improving early detection of 
ovarian cancer. METHODS: A lifetime incremental cost-effectiveness model was con-
structed to calculate the increase of costs, and QALYs gained by the multimodal screen-
ing. In this ‘backward induction’ model, the expected costs and outcomes for each 
5-year time-interval are incorporated in subsequent 5-year time period calculations 
over the patient’s entire lifetime. The sensitivity and speciﬁcity of screening, and the 
stage distribution of detected ovarian cancer by the screening were obtained from the 
NCT00058032 clinical trial. The model used a 3% discount rate and reported results 
in 2009 US dollars. RESULTS: Over a lifetime, multimodal screening was estimated to 
cost an additional $820 with an expected gain of 0.0037 quality adjusted life years 
(QALY) or an incremental cost-effectiveness ratio (ICER) of $221,622/ QALY com-
pared to no screening for age 65–69 postmenopausal females. Compared with annual 
transvaginal ultrasound (TVU) screening, multimodal screening improves cost-effec-
tiveness by avoiding unnecessary TVU and surgery, which are risky to the patient and 
costly to the health care system. Cancer incidence rates and time required for screening 
exhibited substantial impact on the model from sensitivity analyses. CONCLUSIONS: 
Multimodal screening is not clearly cost-effective, compared to commonly accepted 
willingness-to-pay thresholds in oncology ($120,000–$150,000/QALY). If high risk 
women were selected for multimodal screening or if the screening was administered as 
part of another medical ofﬁce visit in order to decrease the time required for screening 
test, the ICER could be lower than $120,000/QALY.
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OBJECTIVES: We conducted an economic evaluation with cost and outcome data 
from a randomized controlled trial of promotora led interventions to increase cervical 
cancer screening among three populations of low income Hispanic women. 
METHODS: Hispanic women of Mexican origin, age 21 to 65, with no previous 
cervical cancer, no hysterectomy, and no Pap test within the last 3 years from El Paso, 
Houston, TX and Yakima Valley, WA were randomly assigned to four intervention 
arms, control, video, ﬂip chart, and full (combination of video and ﬂip chart) interven-
tion. Micro costing, including recruitment cost, from both payer and client perspec-
tives were used to estimate intervention costs. Effectiveness measures were the 
prevalence of a self-reported pap test within 6 months after the intervention, analyzed 
under the condition of intention- to- treat. Incremental cost effectiveness ratios 
(ICERs) were the incremental cost per additional women screened. Uncertainty was 
examined with sensitivity analyses. RESULTS: The total cost per participant, was 
$216 for video, $219 for ﬂip chart, and $223 in the full intervention. The proportion 
of women reporting a Pap test was 0.261 in the control arm, 0.484 in the video arm, 
0.515 in the ﬂipchart arm and 0.568 in the full intervention arm. The ICERs were 
$968 comparing the control arm to the movie, $94 comparing the movie to ﬂip chart 
arm and $72 comparing ﬂip chart to the full intervention arm. CONCLUSIONS: The 
promotora led full interventions had important and statistically signiﬁcant effects on 
screening behavior and compare favorably with the other two strategies designed to 
promote cervical cancer screening in the study. The study provides economic informa-
tion for health educators in designing and budgeting promotora based cancer screening 
promotion programs for low income Hispanic women.
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OBJECTIVES: To assess the cost-effectiveness of an EGFR mutation testing strategy 
when considering 1st-line therapy of aNSCLC with geﬁtinib for mutation positive and 
carboplatin-paclitaxel (CP) for mutation negative disease. METHODS: A Discrete 
Event Simulation (DES) was designed to emulate two strategies for treating patients 
with aNSCLC. In the ﬁrst strategy, patients were tested for EGFR genetic mutation 
and given geﬁtinib if positive and CP if negative. In the second strategy patients were 
not tested for genetic mutation and all of them received CP treatment. Probabilities 
for adverse events and progression-free survival (PFS) were obtained from the IPASS 
clinical study (Mok et al 2009). The mutation rate used was 13% and a sensitivity 
analysis was run over this variable. A Markov model using micro simulation was also 
built to compare results of the DES model and assure internal validity. Both models 
were run 10 times with 1000 patients for each strategy. Cost-effectiveness ratios were 
obtained for the testing and not-testing strategies and particularly for positive tested 
patients treated with geﬁtinib. RESULTS: Mean PFS (generated by DES) of tested 
patients with mutation positive disease treated with geﬁtinib was 11.51 (95% CI, 
11.10–11.92) months. PFS of patients who where tested for EGFR mutation (positive 
and negative) was 7.57 (95% CI, 7.50–7.64) months. Patients in the second strategy 
(without testing) yielded 7.11(95% CI, 7.05–7.17) progression-free months. Incremen-
tal cost-effectiveness ratio (ICER) of the testing strategy (including test cost) over the 
not-testing strategy was $1379.49 (95% IC, $1102.10–$1656.88) per progression-free 
month. CONCLUSIONS: According to this analysis, testing aNSCLC patients for 
